Last checked at 22 Jul 2016 07:00
22 July 2016
Port Erin Biopharma Investments Limited
(the "Company")
Net Asset Value calculation to 30 June 2016
Jim Mellon, Chairman, commented: -
"The Net Asset Value ("NAV") calculation for the Company as at closing on 30 June 2016 was 9.28 pence per share, including un-invested cash of £11,985. The portfolio is valued under IFRS at bid price.
Net Assets stand at £2.2 million including Investments of £2.19 million. This quarter's NAV represents a decrease of 9.11% from the previous valuation of 10.21 pence per share, which included un-invested cash of £10,713. No additional management fee is due to Shellbay Investments Limited.
Unaudited to 30 June 2016 £ | ||
Fixed Assets | ||
Investments | 2,187,075 | |
Current Assets | ||
Sundry Debtors | 7,335 | |
Uninvested cash | 11,985 | |
Current Liabilities | ||
Creditors: amounts due | (54,197) | |
2,152,198 | ||
Capital and Reserves | ||
Share Capital | 23 | |
Share Premium | 1,890,142 | |
Reserves | 262,033 | |
2,152,198 | ||
Shares in Issue | 23,195,558 | |
Net Asset Value per share | 9.28 pence |
Portfolio Details
Investments as at 30 June 2016 | Value | % of Total Portfolio | |
Magna Biopharma Income Fund | £1,231,912 | 56.3% | |
Regent Pacific Group | £249,594 | 11.4% | |
Summit Corporation | £218,291 | 10.0% | |
Other quoted holdings | £85,407 | 3.9% | |
Other unquoted holdings | £401,871 | 18.4% | |
Total | £2,187,075 | 100.0% | |
For further information, please contact:
Port Erin Biopharma Investments Limited | Northland Capital Partners Limited | Peterhouse Capital Limited |
The Company | Nomad and Broker | Joint Broker |
Denham Eke (+44) (0) 1624 639396 | Matthew Johnson / David Hignell (+44) (0) 203 861 6625 | Lucy Williams (+44) (0) 207 469 0936 |